Clinical Trial Detail

NCT ID NCT00866281
Title A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

acute lymphoblastic leukemia

acute myeloid leukemia

Therapies

Midostaurin

Age Groups: child

No variant requirements are available.